Dosage and administration
Apply small amount every 10 minutes for 3 doses immediately after injury, then 2 to 3 times daily. For topical use only.
Apply small amount every 10 minutes for 3 doses immediately after injury, then 2 to 3 times daily. For topical use only.
CALENDULA OFFICINALIS 1X, ARNICA MONTANA 1X, 30C, HYPERICUM PERFORATUM 1X, 30C, SYMPHYTUM OFFICINALE 3X, BELLIS PERENNIS 12X, LEDUM PALUSTRE 12X, SULPHURICUM ACIDUM 12X, CALCAREA FLUORICA 30X, FERRUM PHOSPHORICUM 30X, RHUS TOX 30X, RUTA GRAVEOLENS 30X, NATRUM SULPHURICUM 30C
For temporary relief of pain associated with bumps, bruises, abrasions, strains, sprains, fractures, stiffness; for all minor injuries.**
**These statements are based upon traditional homeopathic practice. They have not been reviewed by the Food and Drug Administration.
For external use only. If an adverse reaction occurs, discontinue use.
If pregnant or breast-feeding, ask a health professional before use.
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Do not use if tamper evident seal is broken or missing.
Store in a cool, dry place. Do not expose product to extreme temperatures.
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Apply small amount every 10 minutes for 3 doses immediately after injury, then 2 to 3 times daily. For topical use only.
For temporary relief of pain associated with bumps, bruises, abrasions, strains, sprains, fractures, stiffness; for all minor injuries.**
**These statements are based upon traditional homeopathic practice. They have not been reviewed by the Food and Drug Administration.
ACRYLATES/C10-30 ALKYL ACRYLATE CROSSPOLYMER (CARBOPOL (ULTREZ 21), ALOE BARBADENSIS LEAF JUICE (ALOE VERA 10X CONCENTRATE), EDETATE DISODIUM (EDTA), NATURAL PLANT EXTRACT (ORIGANOX WS), [PEG-33, PEG-8 DIMETHICONE, PEG-14 (SILSENSE COPOLYOL-1 SILICONE)], [PHENOXYETHANOL, CAPRYLYL GLYCOL, SORBIC ACID (OPTIPHEN-PLUS)], POTASSIUM SORBATE, PURIFIED WATER, SODIUM HYDROXIDE SOLUTION, TOCOPHEROL [VITAMIN E OIL](DERIVED FROM SOY BEAN), WHEY PROTEIN CONCENTRATE+ (DERIVED FROM MILK)
Dist. by Energique, Inc., 201 Apple Blvd.
Woodbine, IA 51579 800.869.8078
ENERGIQUE
SINCE 1987
HOMEOPATHIC REMEDY
TRAUMA+GEL
Net wt. 2 oz. (57 g)
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ARNICA MONTANA | ACTIVE INGREDIENT | O80TY208ZW | 5 | |
| BELLIS PERENNIS | ACTIVE INGREDIENT | 2HU33I03UY | 5 | |
| CALCIUM FLUORIDE | ACTIVE INGREDIENT | O3B55K4YKI | 5 | |
| CALENDULA OFFICINALIS FLOWERING TOP | ACTIVE INGREDIENT | 18E7415PXQ | 5 | |
| COMFREY ROOT | ACTIVE INGREDIENT | M9VVZ08EKQ | 5 | |
| FERROSOFERRIC PHOSPHATE | ACTIVE INGREDIENT | 91GQH8I5F7 | 5 | |
| HYPERICUM PERFORATUM | ACTIVE INGREDIENT | XK4IUX8MNB | 5 | |
| LEDUM PALUSTRE TWIG | ACTIVE INGREDIENT | 877L01IZ0P | 5 | |
| RUTA GRAVEOLENS FLOWERING TOP | ACTIVE INGREDIENT | N94C2U587S | 5 | |
| SODIUM SULFATE | ACTIVE INGREDIENT | 0YPR65R21J | 5 | |
| SULFURIC ACID | ACTIVE INGREDIENT | O40UQP6WCF | 5 | |
| TOXICODENDRON PUBESCENS LEAF | ACTIVE INGREDIENT | 6IO182RP7A | 5 | |
| ARNICA MONTANA | ACTIVE MOIETY | O80TY208ZW | 5 | |
| BELLIS PERENNIS | ACTIVE MOIETY | 2HU33I03UY | 5 | |
| CALENDULA OFFICINALIS FLOWERING TOP | ACTIVE MOIETY | 18E7415PXQ | 5 | |
| COMFREY ROOT | ACTIVE MOIETY | M9VVZ08EKQ | 5 | |
| FERROSOFERRIC PHOSPHATE | ACTIVE MOIETY | 91GQH8I5F7 | 5 | |
| FLUORIDE ION | ACTIVE MOIETY | Q80VPU408O | 5 | |
| HYPERICUM PERFORATUM | ACTIVE MOIETY | XK4IUX8MNB | 5 | |
| LEDUM PALUSTRE TWIG | ACTIVE MOIETY | 877L01IZ0P | 5 | |
| RUTA GRAVEOLENS FLOWERING TOP | ACTIVE MOIETY | N94C2U587S | 5 | |
| SODIUM SULFATE ANHYDROUS | ACTIVE MOIETY | 36KCS0R750 | 5 | |
| SULFURIC ACID | ACTIVE MOIETY | O40UQP6WCF | 5 | |
| TOXICODENDRON PUBESCENS LEAF | ACTIVE MOIETY | 6IO182RP7A | 5 | |
| .ALPHA.-TOCOPHEROL | INACTIVE INGREDIENT | H4N855PNZ1 | 5 | |
| ALOE VERA LEAF | INACTIVE INGREDIENT | ZY81Z83H0X | 5 | |
| CAPRYLYL GLYCOL | INACTIVE INGREDIENT | 00YIU5438U | 5 | |
| CARBOMER COPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) | INACTIVE INGREDIENT | 71DD5V995L | 5 | |
| EDETATE DISODIUM | INACTIVE INGREDIENT | 7FLD91C86K | 5 | |
| OREGANO | INACTIVE INGREDIENT | 0E5AT8T16U | 5 | |
| PEG-8 DIMETHICONE | INACTIVE INGREDIENT | GIA7T764OD | 5 | |
| PHENOXYETHANOL | INACTIVE INGREDIENT | HIE492ZZ3T | 5 | |
| POLYETHYLENE GLYCOL 1500 | INACTIVE INGREDIENT | 1212Z7S33A | 5 | |
| POLYETHYLENE GLYCOL 700 | INACTIVE INGREDIENT | 762678AC5R | 5 | |
| POTASSIUM SORBATE | INACTIVE INGREDIENT | 1VPU26JZZ4 | 5 | |
| SODIUM HYDROXIDE | INACTIVE INGREDIENT | 55X04QC32I | 5 | |
| SORBIC ACID | INACTIVE INGREDIENT | X045WJ989B | 5 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 5 | |
| WHEY | INACTIVE INGREDIENT | 8617Z5FMF6 | 5 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 44911-0138 | 44911-0138-1 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| POLYETHYLENE GLYCOL 1500 | POLYETHYLENE GLYCOL 1600 | 1212Z7S33A | SOLUTION / TOPICAL | 29.7 %w/w | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION, EXTENDED RELEASE / INTRADERMAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRAPERITONEAL | ADJ PH | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SOLUTION/ DROPS / OPHTHALMIC | 0.13 %w/v | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | TABLET, ORALLY DISINTEGRATING / ORAL | 3 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION, EMULSION / INTRAVENOUS | 59 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SPRAY, METERED / NASAL | ADJ PH | ||
| SORBIC ACID | SORBIC ACID | X045WJ989B | TABLET / SUBLINGUAL | 0.16 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / INTRADERMAL | ADJ PH | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET, COATED / ORAL | NA | ||
| POLYETHYLENE GLYCOL 1500 | POLYETHYLENE GLYCOL 1600 | 1212Z7S33A | TABLET, COATED / ORAL | NA | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | ENEMA / RECTAL | 0.44 %v/v | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | GEL / OPHTHALMIC | 6 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | OINTMENT / TOPICAL | ADJ PH | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SYRUP / ORAL | 2 mg/1ml | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRA-ARTERIAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / INTRA-ARTERIAL | ADJ PH | ||
| CARBOMER COPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) | CARBOMER COPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) | 71DD5V995L | LOTION / TOPICAL | 21 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | CAPSULE, LIQUID FILLED / ORAL | 1.5 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION, SOLUTION / INTRAVENOUS | 7 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION, EXTENDED RELEASE / ORAL | 40 mg | ||
| .ALPHA.-TOCOPHEROL | .ALPHA.-TOCOPHEROL | H4N855PNZ1 | TABLET / ORAL | 2 mg | ||
| .ALPHA.-TOCOPHEROL | .ALPHA.-TOCOPHEROL | H4N855PNZ1 | TABLET, EXTENDED RELEASE / ORAL | 4 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | EMULSION / TOPICAL | 0.11 %w/w | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SPRAY / NASAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRATUMOR | ADJ PH | ||
| SORBIC ACID | SORBIC ACID | X045WJ989B | LOTION / TOPICAL | 4 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INFILTRATION | 6 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION, CONCENTRATE / INTRAVENOUS | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INFILTRATION | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | CREAM, AUGMENTED / TOPICAL | 6 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / SUBMUCOSAL | ADJ PH | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SOLUTION / ORAL | 1000 mg/15ml | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAVESICAL | ADJ PH | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | LIQUID / INTRAVENOUS | 0.03 %w/v | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / TOPICAL | 1 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | GEL / OPHTHALMIC | 396 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRALESIONAL | ADJ PH | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | CREAM / TOPICAL | 14 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / OPHTHALMIC | 4 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INTRALESIONAL | 0.05 %w/v | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION, EXTENDED RELEASE / INTRASYNOVIAL | ADJ PH | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SHAMPOO, SUSPENSION / TOPICAL | 1 %w/w | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / RESPIRATORY (INHALATION) | 43 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SPRAY / NASAL | 1 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | GRANULE, FOR SUSPENSION / ORAL | 80 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | FILM, EXTENDED RELEASE / TRANSDERMAL | 0.85 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | POWDER / INTRAVENOUS | ADJ PH | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | ENEMA / RECTAL | 60 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | DISC / TOPICAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTERSTITIAL | ADJ PH | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION/ DROPS / ORAL | 4 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / RECTAL | 97 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | AEROSOL, METERED / RESPIRATORY (INHALATION) | ADJ PH | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | AEROSOL, FOAM / TOPICAL | 72 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAVENOUS | 78 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SWAB / TOPICAL | 0.01 %w/w | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | CAPSULE / ORAL | 60 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 140f49ce-5cbb-4724-b786-8e40dd71d27e | 3585e1f6-2011-4edc-b1e4-9cec24885d68 | 2016-06-28 | Warnings | 140f49ce-5cbb-4724-b786-8e40dd71d27e 3585e1f6-2011-4edc-b1e4-9cec24885d68 |
Adverse event summaries are temporarily unavailable. Other product information remains available.